 |
|
THERAPEUTIC TRIALS OF RADIOGALLIUM (Ga 72)A Report of Four Cases
COMMANDER E. R. KING, (MC);
LIEUTENANT L. W. BRADY, (MC);
COMMANDER H. C. DUDLEY, (MC)
AMA Arch Intern Med. 1952;90(6):785-789.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
|
|
RESULTS of studies of the distribution of gallium and its excretion pattern and toxicity in experimental animals have been reported by Dudley and associates1 and by King and others.2 Clinical trials in the radioactive use of the isotope Ga72 as a possible diagnostic agent for the early localization of malignancies involving bone have been reported by Mulry and Dudley3 and by King and associates.2c Brucer and associates4 have reported upon the results of a therapeutic trial of Ga72.
Radiogallium, 31GA72, is produced by neutron bombardment of natural gallium (Ga39, Ga71) with thermal neutrons, resulting in a mixture of radioactive gallium (Ga70 and Ga72). Ga70 has a half life of 20 minutes and plays no important biological role. Ga72 has a half life of 14.3 hours and is a beta and gamma emitter. The mean effective beta energy equals 0.45 mev, while the gamma emission is 1.59 times as energetic as
. . . [Full Text PDF of this Article]
Author Affiliations
U. S. N.; U. S. N.; U. S. N.
From the Radioisotope Laboratory, United States Naval Hospital, Bethesda, Md. (Commander King and Lieutenant Brady) and the United States Naval Medical Research Institute, Bethesda, Md. (Commander Dudley).
Footnotes
This article has been released for publication by the Division of Publications of the Bureau of Medicine and Surgery of the United States Navy. The opinions or assertions contained herein are the private ones of the authors and are not to be construed as official or reflecting the views of the Navy Department or the Naval Service at large.
|
